title: Prospective evaluation of anthracycline-related early cardiac damage: how do we monitor it?
authors.forename: R
authors.initials: R
authors.lastname: Ciotti
authors.forename: G
authors.initials: G
authors.lastname: Ucci
authors.forename: G
authors.initials: G
authors.lastname: Belotti
authors.forename: E
authors.initials: E
authors.lastname: Facchi
authors.forename: M
authors.initials: M
authors.lastname: Cremonesi
authors.forename: C
authors.initials: C
authors.lastname: Gatti
authors.forename: G
authors.initials: G
authors.lastname: Baccheta
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy; D015251:Epirubicin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011446:Prospective Studies; D015635:Radionuclide Ventriculography; D014463:Ultrasonography; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000139:chemically induced* / Q000000981:diagnostic imaging
chemical_list: D000903:Antibiotics, Antineoplastic; D020097:Natriuretic Peptide, Brain; D015251:Epirubicin